GlassScriptPhysician profile
John I Jones
NPI 1396974234
$63,032.61
in general payments reported to CMS, 2019-2025
47 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,249 · 2020: $2,168 · 2021: $3,385 · 2022: $2,293 · 2023: $2,713 · 2024: $26K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K · Food and Beverage: $8,811 · Honoraria: $5,163 · Travel and Lodging: $3,321 · Education: $4.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,837.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $14,800.00 |
| Food and Beverage | $8,811.12 |
| Honoraria | $5,163.00 |
| Travel and Lodging | $3,321.09 |
| Education | $4.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $17,762.92 | 2022-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $16,203.65 | 2021-2025 | Korlym |
| Abbvie INC. | $11,891.09 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,692.26 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $3,329.66 | 2019-2025 | |
| Novo Nordisk INC | $1,824.29 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,283.63 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $1,049.40 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $978.59 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Xeris Pharmaceuticals, INC. | $767.16 | 2021-2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $605.09 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $536.65 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $519.84 | 2019-2025 | |
| Medtronic, INC. | $361.89 | 2021-2025 | Minimed 780g |
| Novartis Pharmaceuticals Corporation | $341.89 | 2019-2024 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.